Repository of Research and Investigative Information

Repository of Research and Investigative Information

Baqiyatallah University of Medical Sciences

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis

(2017) Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. Annals of Hepatology. pp. 188-197. ISSN 1665-2681

[img] Text
Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection Systematic Review and Meta-Analysis.pdf

Download (277kB)

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

Background and aim. The combination of Sofosbuvir (SOF) and Ledipasvir (LDV) has been lead to considerable enhancement of treatment of hepatitis C virus (HCV) genotype 1 infection. A meta-analysis of the currently available studies was undertaken with the aim to evaluate the antiviral efficacy of SOF/LDV therapy for 12 or 24 weeks with or without Ribavirin (RBV) in patients with HCV genotype 1 infection. Material and methods. In this meta-analysis, we searched databases including PubMed, Scopus, Science Direct and Web of Science using appropriate keywords. All papers which evaluated the efficacy of combination therapy of SOF/LDV with or without RBV for 12 or 24 weeks among patients with HCV genotype 1 infection were included. Results. The 20 published articles were assessed for eligibility and finally 10 articles pooling 2248 participants were included in this meta-analysis. Pooled SVR12 for four SOF/LDV regimens were 95 (95CI = 93-97) for 12 weeks of treatment with SOF/LDV, 97 (95CI = 95-98) for 24 weeks of treatment with SOF/LDV, 96 (95CI = 94-97) for 12 weeks for treatment with SOF/LDV/RBV and 98 (95CI = 97-99) for 24 weeks of treatment with SOF/LDV for 12 weeks cirrhosis had a significant effect on the SVR12(OR = 0.21, 95CI = 0.2-0.5). Conclusion. The Interferon-free regimen of SOF/LDV for 12 or 24 weeks with or without RBV is highly effective for treatment of patients with HCV genotype 1 infection.

Item Type: Article
Keywords: Hepatitis C Therapy Sofosbuvir Ledipasvir Meta-analysis fixed-dose combination treatment-naive open-label ribavirin hcv therapy plus peginterferon elbasvir Gastroenterology & Hepatology
Divisions:
Page Range: pp. 188-197
Journal or Publication Title: Annals of Hepatology
Journal Index: ISI
Volume: 16
Number: 2
Identification Number: https://doi.org/10.5604/16652681.1231562
ISSN: 1665-2681
Depositing User: مهندس مهدی شریفی
URI: http://eprints.bmsu.ac.ir/id/eprint/4529

Actions (login required)

View Item View Item